Construction and internal validation of a preoperative prediction model for lymphatic metastasis in endometrial cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054282

Enrollment

Unknown

Registered

2021-12-12

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial carcinoma

Interventions

Gold Standard:Clinical outcome

Index test:Endometrial&#32

cancer&#32

prediction&#32

model

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Cases with biopsy-proven endometrial cancer. 2. Preoperative pelvic MRI and (or) intraoperative rapid freezing examination to evaluate preoperative tumor staging. 3. Preoperative curettage and (or) intraoperative quick freezing examination to evaluate tumor tissue type and grade. 4. Determination of serum ca125 level before operation. 5. Special types of endometrial cancer (serous, clear cell, dedifferentiated, mucinous, neuroendocrine, papillary, and squamous cell carcinomas, etc.) are considered to be grade 3.

Exclusion criteria

Exclusion criteria: 1. The pathological type is uterine smooth muscle stromal sarcoma or endometrial stromal sarcoma. 2. Patients receiving neoadjuvant chemotherapy. 3. Patients with other primary synchronous malignant tumors. 4. Patients with incomplete medical records.

Design outcomes

Primary

Measure	Time frame
Pathological results;Accuracy, specificity, sensitivity;Positive predictive value, negtive predictive value;	—

Countries

China

Contacts

Public ContactZheng Hui

Fujian Maternal and Child Health Hospital

834720396@qq.com+86 15880435941

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026